TFA
ADCT icon

Toth Financial Advisory’s ADC Therapeutics ADCT Stock Holding History

Toth Financial Advisory’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-70
Closed -$1K – 709
2021
Q4 		$1K Hold
70
– – ﹤0.01% 677
2021
Q3 		$2K Hold
70
– – ﹤0.01% 632
2021
Q2 		$2K Hold
70
– – ﹤0.01% 577
2021
Q1 		$2K Buy
+70
New +$2.03K ﹤0.01% 572

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Toth Financial Advisory's ADCT Position: Q1 2022 in Review

Toth Financial Advisory sold out of ADC Therapeutics (ADCT) in Q1 2022, closing a stake of 70 shares — an estimated $1K sold.

Toth Financial Advisory first reported a position in ADCT in Q1 2021 and held it in 4 quarters. The position peaked at $2K in Q3 2021. 49 funds tracked by Wall St. Rank hold ADCT as of Q1 2022.

  • Toth Financial Advisory reported no remaining ADC Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Toth Financial Advisory sold 70 ADC Therapeutics shares in Q1 2022, an estimated $1K.
  • Toth Financial Advisory first reported a position in ADC Therapeutics in Q1 2021 and held it in 4 quarters.
  • Toth Financial Advisory's ADC Therapeutics position peaked at $2K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2022.

Based on Toth Financial Advisory's 13F filing for Q1 2022, filed 26 Apr 2022.